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A. BACKGROUND 
Tuberculosis is a major disease causing every year 1.8 million deaths worldwide and represents 
the leading cause of mortality resulting from a bacterial infection. Introduction in the 60’s of 
first-line drug regimen resulted in the control of the disease and TB was perceived as defeated.  
 
In 2011, tuberculosis (TB) remained the second cause of death from infectious disease 
worldwide. It mainly affects the poorest countries of Africa and Southeast Asia. In 2010, 
according to the World Health Organization (WHO), TB incidence and prevalence were 
estimated at 8.8 and 12 million cases respectively. 1.1 million among HIV-negative people and 
0.35 million among HIV-positive people died from TB . Most importantly, one third of the world 
population is infected with latent infection and 10% of those infected people will develop active 
TB in their life.  
 
The directly observed treatment short-course (DOTS), a multidrug therapy program developed 
by WHO is one of the most efficient weapons against the global TB epidemic. Nevertheless, the 
treatment success rate struggles to reach the target of 85%. Unfortunately, first-line treatment can 
fail due to poor compliance which leads to the emergence of multidrug resistant (MDR) strains 
of M. tuberculosis. Anti-tuberculosis agents in current development trigger a large panel of 
biological pathways such as cell wall synthesis, protein synthesis or membrane energy 
production. The number of TB drugs in preclinical and clinical development is today higher than 
during the past 40 years. 
 
Current Therapies: 
 
 In 1944, streptomycin was the first compound used to treat TB. This amino glycoside interferes 
with protein biosynthesis through an interaction with the small 30S subunit of the ribosome. The 
discovery of para-aminosalicylic acid in 1946 was quickly followed by the important 
identification of isoniazid (INH), one of the most active anti-TB drug used today. Inhibition of 
mycolic acids biosynthesis, one of the essential components of the mycobacterial cell wall was 
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determined as isoniazid mechanism of action. Pyrazinamide (PZA) appeared as a potential TB 
drug in 1952. Its introduction in the TB treatment in the 1980s was a great success as it allowed 
to shorten the duration of the TB therapy from 9 to 6 months. Ethambutol (EMB) and rifampin 
(RIF), the two last derivatives used in the TB first-line treatment, were discovered during the 
60’s. Ethambutol is an ethylenediamine discovered in 1961, which affects the cell wall by 
specifically targeting the polymerization of arabinogalactane and lipoarabinomannane. Finally, 
rifampin appeared as a drug of choice for TB treatment around 1970, by acting on replicating 
and non-replicating mycobacteria. This derivative belongs to the rifamycine family and inhibits 
bacterial RNA synthesis by binding to the b-subunit of the DNA-dependent polymerase.  
 
The current standard regimen (DOTS) for TB recommended by WHO is a combination of 
isoniazid, rifampin, ethambutol and pyrazinamide for a 6 months therapy. To treat MDR-TB, 
WHO recommends the use of second-line drugs which include aminoglycosides (kanamycin, 
amikacin), capreomycin, cycloserin, para-aminosalicylic acid, thioamides (ethionamide (ETH), 
prothionamide), and fluoroquinolones
[1] 
(ciprofloxacin, ofloxacin, levofloxacin). Ethionamide 
and prothionamide are isoniazid analogues discovered in 1956. 
[1] 
 
Fluoroquinolones gatifloxacin and moxifloxacin (Phase 3) oxazolidinone linezolid and 
nitroimidazole metronidazole (Phase 2) have been repurposed for tuberculosis. New chemical 
entities have also progressed in clinical development based on optimization of known chemical 
scaffolds: this is the case for nitroimidazole derivatives OPC-67683 and PA-824 both in phase 2, 
substituted ethylenediamine SQ109 (phase 2), oxazolidinone analogues PNU- 100480 (phase 2) 
and AZD5847 (phase 1). Finally, promising diarylquinoline TMC207, first compound of a new 
class of antituberculosis drugs is currently being evaluated in Phase 2.
[1] 
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B.  BACTERIOLOGICAL PROFILE OF MYCOBACTERIUM 
TUBERCULOSIS: 
SPECIES:  
The Mycobacterium tuberculosis complex (MTC) consists of Mycobacterium africanum, 
Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti, Mycobacterium 
pinnipedii and Mycobacterium canettii. 
[2] 
Tuberculosis (TB) is a bacterial infectious disease caused by the obligate human pathogen, 
Mycobacterium tuberculosis. Mycobacteria are a distinctive rod shaped, non spore forming 
aerobic bacteria that share a common property of a  lipid-rich cell wall that avidly retains 
Carbol fuchsin dye  in the presence of acidic alcohol (acid fast staining), Mycobacteria 
typically measure 0.5 μm by 3μm [3] 
 
CELL STRUCTURE:  
In 1882, Robert Koch identified Mycobacterium tuberculosis as the causative agent of TB.  
M. tuberculosis belongs to the order Actinomycetales. Mycobacterium tuberculosis is a slow-
growing aerobic rod-shaped bacterium. The cell wall is composed of two segments, upper 
and lower. Beyond the membrane is peptidoglycan (PG) in covalent attachment to 
arabinogalactan (AG), which in turn is attached to the mycolic acids with their long 
meromycolate and short α-chains. This is the cell wall core the mycolyl arabinogalactan–
peptidoglycan (mAGP) complex. The upper segment is composed of free lipids, some with 
longer fatty acids complementing  the  shorter α-chains, and some with shorter fatty acids 
complementing the longer chains. Interspersed with the cell-wall proteins are the 
phosphatidylinositol mannosides (PIMs), the phthiocerol containing lipids, lipomannan (LM), 
and lipoarabinomannan (LAM). When cell walls are disrupted, for instance extracted with 
various solvents, the free lipids, proteins, LAM, and PIMs are solubilized, and the mycolic 
acid–arabinogalactan– peptidoglycan complex remains as the insoluble residue. [4] 
 
 
                                                                                                       Introduction 
 
Department of Pharmaceutical Chemistry Page 4 
 
 
 
GENOME STRUCTURE: 
Mycobacterium tuberculosis H37Rv was first isolated in 1905, has remained pathogenic and 
is the most widely used strain in tuberculosis research. The complete genome sequence and 
annotation of this strain was published in 1998 (Cole et al., 1998⇓ ).  Approximately 9% of 
the M. tuberculosis genome consists of two related families of genes that have been named 
the PE and PPE families (cole et al., 1998). These names derive from the presence of 
conserved proline glutamate (PE) or proline-proline-glutamate (PPE) residues near the N 
terminus of the predicted proteins of the family. These predicted protein share a conserved N 
terminal domain of ~ 110 amino acids (PE) or 180 aminoacdis(PPE) with divergent C-
terminal sequences. A subfamily of the PE family has been designated the PGRS proteins 
based on C-terminal extensions rich in a repetitive glycine/alanine (GA) motif. A large 
portion of the coding capacity of the M. tuberculosis genome is putatively involved with lipid 
biosynthesis or lipid degradation. 
[3] 
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As per March 2013 in  TubercuList  there are 
[5]
  
 4,411,532 bp of DNA sequence representing the whole Mycobacterium tuberculosis 
chromosome (strain H37Rv)  
 4,018 protein genes  
 13 pseudogenes  
 45 tRNA genes  
 3 rRNA genes  
 30 ncRNA genes  
 2 miscRNA genes 
 Gene density: 0.91 genes per kb  
 Average length: 1,002 bases per gene  
 Protein coding bases: 4,027,296  
 Protein coding percentage: 91.2%  
 GC percentage: 65.9 % 
 
CHOLESTEROL CATABOLISM: 
Cholesterol metabolism has been studied extensively because of its possible therapeutic 
applications in Tuberculosis(TB) infections. It has been shown numerous times that TB 
infections require cholesterol for virulence in vivo, because Mycobacterium tuberculosis 
(MTB), the causative agent, utilizes cholesterol as an electron and carbon source during 
infection .  
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M. tuberculosis bacterial colonies 
 
 
 
 
Scanning Electron Microscopic Image of M.tuberculosis 
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PATHOPHYSIOLOGY OF M.tuberculosis: 
 
Mycobacterium tuberculosis is spread by small airborne droplets,called droplet nuclei. 
Once inhaled, the infectious droplets settle throughout the airways. The majority of the bacilli 
are trapped in the upper parts of the airways where the mucus-secreting  goblet cells exist. 
Bacteria in droplets that bypass the mucociliary system and reach the alveoli are quickly 
surrounded and engulfed by alveolar macrophages, the most abundant immune effector cells 
present in alveolar spaces. The mycobacterial lipoarabinomannan is a key ligand for a 
macrophage receptor. The complement protein C3 binds to the cell wall and enhances 
recognition of the mycobacteria by macrophages. Opsonization by C3 is rapid, even in the air 
spaces of a host with no previous exposure to M tuberculosis. After being ingested by 
macrophages, the mycobacteria continue to multiply slowly, with bacterial cell division 
occurring every 25 to 32 hours. Regardless of whether the infection becomes controlled or 
progresses, initial development involves production of proteolytic enzymes and cytokines by 
macrophages in an attempt to degrade the bacteria. Released cytokines attract T lymphocytes 
to the site, the cells that constitute cell-mediated immunity. Macrophages then present myco -
bacterial antigens on their surface to the T cells. This initial immune process continues for 2 
to 12 weeks; the microorganisms continue to grow until they reach sufficient numbers to fully 
elicit the cell-mediated immune response, which can be detected by a skin test.  
For persons with intact cell mediated immunity, the next defensive step is formation of 
granulomas around the M tuberculosis organisms.  These nodular-type lesions form from an 
accumulation of activated T lymphocytes and macrophages, which creates a 
microenvironment that limits replication and the spread of the mycobacteria. 
M tuberculosis organisms can change their phenotypic expression, such as protein regulation, 
to enhance survival. By 2 or 3 weeks, the necrotic environment resembles soft cheese, often 
referred to caseous necrosis, and is characterized by low oxygen levels, low pH, and limited 
nutrients. 
[6]
  
M. tuberculosis requires oxygen to grow. Ziehl-Neelsen staining or acid-fast staining, is used. 
[6]
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MICROSCOPY: 
Owing to their high lipid content in cell walls, M.tuberculosis cannot be identified by Gram’s 
staining. Acid-Fast staining or Ziehl-Neelsen staining is employed to identify the organisms. 
M. tuberculosis is characterized by caseating granulomas containing Langhans giant cells, 
which have a "horseshoe" pattern of nuclei. Organisms are identified by their red color on 
acid-fast staining. 
 
 
 
Acid-Fast staining showing caseating granulomas containing Langhans giant cells, which 
have a "horseshoe" pattern of nuclei. 
 
DIAGNOSIS: 
Tuberculin skin test 
Tuberculin skin test, also called as Mantoux skin test, has been used for the diagnosis of 
tuberculosis for more than a century. Despite the numbers of logistic and performance 
problems and poor specificity, TST is still performed as a routine diagnostic method. The 
purified protein derivative (PPD) antigens, that are used for TST are highly homologous to 
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antigens of Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine and 
nontuberculosis mycobacteria (NTM) antigens. The test is based on a delayed-type 
hypersensitivity (DTH) response to a complex cocktail of M. tuberculosis antigens, known as 
purified protein derivative (PPD). The induration of more than 5mm, recorded 48 to 72 hours 
after injection of PPD, is considered as positive.
 [7] 
 
Interferon Gamma Releasing Assay (IGRA) 
IFN is a cytokine that plays a critical role in resistance to Mycobacterium 
tuberculosis infection and MTB infected individuals respond to MTB antigen stimulation by 
releasing increased amounts of this cytokine from effector memory cells, methods based on 
measuring the IFN production by antigen stimulated human T lymphocytes have been 
developed. More sensitive and specific tests such as cell-mediated immunity-based 
interferon-gamma (IFN-γ) release assays (IGRAs) have also been developed that detect T cell 
responses after stimulation by two M. tuberculosis-specific antigens, early secreted antigenic 
target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10). Two commercial IGRAs, whole 
blood, ELISA-based QuantiFERON (QFN)-TB Gold assay (Cellestis Ltd., Carnegie, 
Australia) and peripheral blood mononuclear cell (PBMC) and enzyme-linked immunospot 
(ELISPOT) technology-based T SPOT-TB (Oxford Immunotec, Oxford, UK) test have also 
been developed and approved by Food and Drug Administration (FDA) for detecting LTBI. 
[7] 
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C. MEDICINAL CHEMISTRY- AN INTRODUCTION AND A 
HISTORY 
 
Medicinal chemistry, “tries to be based on the ever increasing hope that biochemical rationales 
for drug discovery may be found” [8]. Pharmaceutical Chemistry is a subject concerned primarily 
with modification of structures having known physiologic and pharmacologic effects and with 
analysis of drugs 
[8] 
 
In the so-called pre-scientific period, natural products having a history as folk remedies were in 
use, but little of the drug therapy of today is based on these remedies. Some of the natural 
products currently used either themselves or as derivatives, were often used originally for other 
purposes, such as arrow poisons, part of religious or other rituals, or even cosmetics. Examples 
of such products include opium, belladonna, cinchona bark, ergot, curare, nutmeg, calabar bean, 
foxglove and squill. 
[8] 
 
Development of drug therapy could not progress until knowledge of anatomy and physiology 
had reached the status of science. The empiric observations of Harvey and Sydenham were of 
great importance to this development in the seventeenth century. The work of Magendie (1783-
1855), an instructor of anatomy in Paris, probably represents the earliest application of the 
experimental medicine. 
[8] 
 
Following the French Revolution, the study and classification of diseases made considerable 
progress. Ineffective remedies were recognized and discarded. In Germany, much of the drug 
discovery in the nineteenth century resulted from the investigations in the chemical industries 
mainly concerned with dyes. It was not until twentieth century, that the search for new drug 
entities or classes took place in university laboratories. 
[8] 
 
The concept of the drug-receptor interaction has undergone much modification from1960s to the 
1990s. The use of computer graphics to portray drug-receptor interaction has also been a notable 
development during the past decade. 
[8] 
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The approach to practice of medicinal chemistry has developed from an empiric one involving 
organic synthesis of new compounds, based largely on modification of structures of known 
activity, to one that is more logical and less intuitive is mostly because of advancements in 
Molecular Biology, Pharmacology, and Enzymology. 
[8] 
 
The primary objective of medicinal chemistry is to design and discover new compounds that are 
suitable for use as drugs. 
[9] 
 
The discovery or design of a new drug not only requires a discovery or design process, but also 
synthesis of the drug, a method of administration, the development of tests and procedures to 
establish how it operates in the body and safety assessment. Drug discovery also requires 
fundamental research into biological and chemical nature of the diseased state. 
[9]
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D. DRUG DESIGN PROFILE: 
The phrase "drug design" is to some extent a misnomer 
[10]
. What is really meant by drug design 
is ligand design (i.e., design of a small molecule that will bind tightly to its target). Drug design 
involves the design of small molecules that are complementary in shape and charge to the 
bimolecular target with which they interact and therefore will bind to it. Drug design, sometimes 
referred to as rational drug design or more simply rational design is the inventive process of 
finding new medications based on the knowledge of a biological target. The drug is most 
commonly an organic small molecule that activates or inhibits the function of a biomolecule such 
as a protein, which in turn results in a therapeutic benefit. 
 
There are two major types of drug design. The first is referred to as ligand-based drug design and 
the second, structure-based drug design. 
[10] 
 
TYPES OF DRUG DESIGN: 
LIGAND BASED DRUG DESIGN: 
Ligand-based drug design or indirect drug design relies on knowledge of other molecules that 
bind to the biological target of interest. These other molecules may be used to derive a 
pharmacophore model that defines the minimum necessary structural characteristics a molecule 
must possess in order to bind to the target. Quantitative structure-activity relationship (QSAR), 
in which a correlation between calculated properties of molecules and their experimentally 
determined biological activity, may be derived. These QSAR relationships in turn may be used to 
predict the activity of new analogs. 
[10] 
 
STRUCTURE BASED DRUG DESIGN: 
Structure-based drug design or direct drug design relies on knowledge of the three dimensional 
structure of the biological target obtained through methods such as x-ray crystallography or 
                                                                                                            Introduction 
 
Department of Pharmaceutical Chemistry Page 13 
 
NMR spectroscopy. If an experimental structure of a target is not available, it may be possible to 
create a homology model of the target based on the experimental structure of a related protein. 
Using the structure of the biological target, drugs that are predicted to bind with high affinity and 
selectivity to the target may be designed using interactive graphics and the intuition of a 
medicinal chemist. As experimental methods such as X-ray crystallography and NMR develop, 
the amount of information concerning 3D structures of biomolecular targets has increased. 
Current methods for structure-based drug design can be divided roughly into two categories. The 
first category is about finding ligands for a given receptor, which is usually referred as database 
searching. In this case, a large number of potential ligand molecules are screened to find those 
fitting the binding pocket of the receptor. The key advantage of database searching is that it 
saves synthetic effort to obtain new lead compounds. Another category of structure-based drug 
design methods is about building ligands, which is usually referred as receptor-based drug design 
. In this case, ligand molecules are built up within the constraints of the binding pocket by 
assembling small pieces in a stepwise manner. These pieces can be either individual atoms or 
molecular fragments. 
[10] 
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ACTIVE SITE IDENTIFICATION: 
Active site identification is the first step. It analyzes the protein to find the binding pocket, 
derives key interaction sites within the binding pocket, and then prepares the necessary data for 
ligand fragment link. Both ligand and protein atoms need to be classified and their atomic 
properties should be defined, basically, into four atomic types: 
 Hydrophobic atom: All carbons in hydrocarbon chains or in aromatic groups.  
 H-bond donor: Oxygen and nitrogen atoms bonded to hydrogen atom(s).  
 H-bond acceptor: Oxygen and sp
2
 or sp hybridized nitrogen atoms with lone electron 
pair(s).  
 Polar atom: Oxygen and nitrogen atoms that are neither H-bond donor nor H-bond 
acceptor, sulfur, phosphorus, halogen, metal, and carbon atoms bonded to hetero-atom(s). 
[10] 
SCORING METHOD: 
Structure-based drug design attempts to use the structure of proteins as a basis for 
designing new ligands by applying accepted principles of molecular recognition. The 
structure-based drug design is that a good ligand molecule should bind tightly to its 
target. One of the most important principles for designing or obtaining potential new 
ligands is to predict the binding affinity of a certain ligand to its target. 
[10] 
SCREENING AND DESIGN: 
The process of finding a new small molecule (ligand) against a chosen target for a particular 
disease usually involves high-throughput screening (HTS).  
The structure-activity relationships (SAR) is to improve certain features of the lead compound: 
 increase activity against the chosen target  
 reduce activity against unrelated targets  
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 improve the drug likeness or ADME properties of the molecule.  
This process will require several iterative screening runs, during which, it is hoped, the 
properties of the new molecular entities will improve, and allow the favoured compounds to go 
forward to in vitro and in vivo testing for activity in the disease model of choice. 
A range of parameters can be used to assess the quality of a compound, or a series of 
compounds, as proposed in the Lipinski's Rule of Five. Such parameters include calculated 
properties such as cLogP to estimate lipophilicity, molecular weight, polar surface area and 
measured properties, such as potency, in-vitro measurement of enzymatic clearance etc. Some 
descriptors such as ligand efficiency (LE) and lipophilic efficiency (LiPE) combine such 
parameters to assess druglikeness. 
Other methods, such as virtual high throughput screening, where screening is done using 
computer-generated models and attempting to "dock" virtual libraries to a target, are also often 
used. 
Another important method for drug discovery is drug design, whereby the biological and 
physical properties of the target are studied, and a prediction is made on  the sorts of small 
molecules that might (e.g.) fit into an active site. One example is fragment-based lead discovery 
(FBLD). Novel pharmacophores can emerge very rapidly from these exercises. In general, 
computer-aided drug design is often used to try to improve the potency and properties of new 
drug leads. 
[8]
 
COMPUTER-AIDED DRUG DESIGN  
Computer-aided drug design uses computational chemistry to discover, enhance, or study drugs 
and related biologically active molecules. Molecular mechanics or molecular dynamics are most 
often used to predict the conformation of the small molecule and to model conformational 
changes in the biological target that may occur when the small molecule binds to it. 
Molecular mechanics methods may also be used to provide semi-quantitative prediction of the 
binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity 
estimates.  
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Drug design with the help of computers may be used at any of the following stages of drug 
discovery: 
[10] 
1. hit identification using virtual screening (structure- or ligand-based design)  
2. hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, etc.)  
3. lead optimization: optimization of other pharmacokinetic properties while maintaining 
affinity.  
In order to overcome the insufficient prediction of binding affinity calculated by recent scoring 
functions, the protein-ligand interaction and a compound’s 3D structure information are used for 
analysis. 
[10]  
 
MOLECULAR PROPERTY  PREDICTION: 
All the data set molecules were subjected to the toxicity risk assessment by using Osiris program, 
which is available online. The OSIRIS property Explorer shown in this page is an integral part of 
Actelion's in house substance registration system. It allows drawing chemical structures and also 
calculates various drug relevant properties whenever a structure is valid. Prediction results are 
color coded in which the red colour shows high risks with undesired effects like mutagenicity or 
a poor intestinal absorption and green colour indicates drug-conform behavior. 
Molecular property prediction includes 
 Toxicity risk assessment 
 clogP predicition 
 Solubility prediction 
 Molecular weight 
 Drug likeness prediction 
 Drug likeness score 
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TOXICITY RISK ASSESSMENT: 
               On drawing a structure the toxicity risk predictor will start looking for potential toxicity 
risks as long as the currently drawn structure is a valid chemical entity. Toxicity risk alerts are an 
indication that the drawn structure may be harmful concerning the risk category specified. The 
prediction process relies on a precomputed set of structural fragment that give rise to toxicity 
alerts in case they are encountered in the structure currently drawn. These fragment lists were 
created by rigorously shreddering all compounds of the RTECS database known to be active in a 
certain toxicity class like mutagenicity, Tumorigenicity, Irritating effects and Reproductive 
effects. 
[11] 
clogP PREDICTION: 
The logP value of a compound, which is the logarithm of its partition coefficient between n-
octanol and water log(coctanol/cwater), is a well established measure of the compound's 
hydrophilicity. Low hydrophilicities and therefore high logP values cause poor absorption or 
permeation. clogP value must not be greater than 5.0 for permeability. 
[11] 
SOLUBILITY PREDICTION: 
The aqueous solubility of a compound significantly affects its absorption and distribution 
characteristics. Typically, a low solubility goes along with a bad absorption and therefore the 
general aim is to avoid poorly soluble compounds. 
[11] 
MOLECULAR WEIGHT: 
Optimizing compounds for high activity on a biological target almost often goes along with 
increased molecular weights. However, compounds with higher weights are less likely to be 
absorbed and therefore to ever reach the place of action. Thus, trying to keep molecular weights 
as low as possible should be the desire of every drug forger. 
[11] 
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DRUG LIKENESS: 
Druglikeness is a qualitative concept used in drug design for how "druglike" a substance is with 
respect to factors like bioavailability. It is estimated from the molecular structure before the 
substance is even synthesized and tested. A druglike molecule has properties such as:Solubility 
in both water and fat, as an orally administered drug needs to pass through the intestinal lining 
after it is consumed, carried in aqueous blood and penetrate the lipid cellular membrane to reach 
the inside of a cell. A model compound for the lipophilic cellular membrane is octanol (a 
lipophilic hydrocarbon), so the logarithm of the octanol/water partition coefficient, known as 
LogP, is used to predict the solubility of a potential oral drug. This coefficient can be 
experimentally measured or predicted computationally, in which case it is sometimes called 
"cLogP". 
[11] 
LIPINSKI’S RULE OF FIVE: [12,13] 
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule of 
five (RO5) is to evaluate druglikeness or determine if a chemical compound with a 
certain pharmacological or biological activity has properties that would make it a 
likely orally active drug in humans. The rule was formulated by Christopher A. 
Lipinski in 1997. 
The rule describes molecular properties important for a drug’s pharmacokinetics in 
the human body, including their absorption, distribution, metabolism, and excretion 
("ADME"). However, the rule does not predict if a compound is pharmacologically 
active. 
Lipinski's rule states that, in general, an orally active drug has no more than one 
violation of the following criteria: 
Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or 
more hydrogen atoms) 
Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
A molecular mass less than 500 daltons 
An octanol-water partition coefficient log P not greater than 5. 
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E. ENZYME PROFILE 
 
Resistance against currently used antitubercular therapeutics increasingly undermines efforts to 
contain the worldwide tuberculosis (TB) epidemic. Recently, benzothiazinone (BTZ) inhibitors 
have shown nanomolar potency against both drug-susceptible and multidrug-resistant strains of 
the tubercle bacillus. However, their proposed mode of action is lacking structural evidence. The 
crystal structure of the BTZ target, FAD-containing oxidoreductase Mycobacterium tuberculosis 
DprE1, which is essential for viability.  
 
Different crystal forms of ligand-free DprE1 reveal considerable levels of structural flexibility of 
two surface loops that seem to govern accessibility of the active site. Structures of complexes 
with the BTZ-derived nitroso derivative CT325 reveal the mode of inhibitor binding.  
 
More recently nitro-benzothiazinones (BTZs) have emerged as a promising class of  inhibitors,  
effective against both drug-susceptible and MDR/XDR strains of Mycobacterium tuberculosis at 
significantly lower minimum inhibitory concentrations (MICs) than either isoniazid or 
rifampicin, in combination with reduced toxicity. 
 
Biochemical studies showed that rv3790 and the neighboring gene rv3791 code for proteins that 
act in concert to catalyze the  epimerization of decaprenylphosphoryl ribose (DPR) to 
decaprenylphosphoryl arabinose (DPA) , a precursor for arabinan synthesis without which a 
complete mycobacterial cell wall cannot be produced. 
 
DPA is the sole known donor substrate for a series of membrane-embedded 
arabinosyltransferases, including the ethambutol targets EmbC, EmbA, and EmbB (9). 
Essentiality of  DPA supply and lack of alternative synthetic pathways position  DprE1, which is 
highly conserved in mycobacteria, and DprE2 at a critical intersection of  cell wall biosynthesis, 
a notion confirmed by transposon mutagenesis. This situation has led DprE1 as a magic drug 
target. 
[14] 
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General annotation 
[15]
 
 
 
 
 
 
 
  
Gene name dprE1 
Rv number Rv3790 
  
Type CDS 
Function 
Together with DPRE2|Rv3791, catalyzes epimerization of 
decaprenylphosphoryl ribose (DPR) to decaprenylphosphoryl 
arabinose (DPA) in arabinan synthesis 
Product Decaprenylphosphoryl-beta-D-ribose 2'-oxidase 
  
Molecular mass (Da) 50163.2 
Isoelectric point 7.769 
Gene length (bp) 1386 
Protein length 461 
Location (kb) 4235.78 
Functional category lipid metabolism 
Proteomics 
Identified in the membrane fraction of M. tuberculosis H37Rv 
using 1D-SDS-PAGE and uLC-MS/MS (See Gu et al., 2003). 
Identified in the cell membrane fraction of M. tuberculosis 
H37Rv using 2DLC/MS (See Mawuenyega et al., 2005). 
Identified by mass spectrometry in Triton X-114 extracts of 
M. tuberculosis H37Rv (See Malen et al., 2010). Identified by 
mass spectrometry in the membrane protein fraction and 
whole cell lysates of M. tuberculosis H37Rv but not the 
culture filtrate (See de Souza et al., 2011). Translational start 
site supported by proteomics data (See Kelkar et al., 2011). 
 
 
Mutation 
essential gene by Himar1-based transposon mutagenesis in 
H37Rv strain (see Sassetti et al., 2003). Essential gene for in 
vitro growth of H37Rv, by sequencing of Himar1-based 
transposon mutagenesis (See Griffin et al., 2011).  
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F. BIOLOGICAL ACTIVITIES OF DIHYDYDROPYRIMIDINONES 
 
N
N  
Pyrimidine is a six membered heterocyclic ring having two nitrogen (N) atoms in their ring. 
Pyrimidine having molecular formula of C4H4N2 Pyrimidine is a colourless compound, having 
melting point 22.50C and boiling point 1240C. Pyrimidines can be considered best as derivatives 
of pyridine and, to a lesser extent, as cyclic amidines. Pyrimidine, which accepts two protons 
under extremely acidic conditions (pKa1 1.3 pKa2 6.9), is much weaker base than pyridine (pKa 
5.23), imidazole (pKa 7.2), or amidines in general. 
In medicinal chemistry pyrimidine derivatives have been very well known for their therapeutic 
applications. The presence of a pyrimidine base in thymine, cytosine and uracil, which are the 
essential building blocks of nucleic acids, DNA and RNA is one of the possible reasons for their 
activities. 
[16] 
DIHYDROPYRIMIDINONES 
The first synthesis of dihydropyrimidinones was reported by Biginelli  in 1893. 
NH
N
H
O
R
1
R
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In 1893, P Bigenelli reported on the acid catalyzed cyclo-condensation reaction of ethyl 
acetoacetate, benzaldehyde, and urea . The reaction was carried out by simply heating a mixture 
of the three components dissolved in ethanol with a catalytic amount of hydrochloric acid at 
reflux temperature. The product of this novel one-pot, three components synthesis that 
precipitated on cooling of the reaction mixture was identified as 3,4-dihydropyrimidin-2(1H)-one 
and this reaction is known as “Biginelli reaction”, or “Biginelli Condensation”, or as “Biginelli 
dihydropyrimidine synthesis”. [17] 
 
The first mechanism for the synthesis of dihydropyrimidine (Biginelli reaction) were conducted 
by Folkers and Johnson in 1933. In 1973, a second mechanistic proposal was suggested by Sweet 
and Fissekis. In 1997, the mechanism was provided by Kappe whose proposal is currently the 
accepted mechanism for the Biginelli reaction. 
 
 
 
 
Kappe35(1997) 
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BIOLOGICAL ACTIVITY  
 
Biginelli type dihydropyrimidines have received a considerable amount of attention, due to 
interesting pharmacological property associated with calcium channel blocker activity, 
antihypertensive activity, antibacterial and antimicrobial activity. 
ANTI-TUBERCULAR ACTIVITY : 
Dihydro pyrimidines also were evaluated for their antitubercular activity against Mycobacterium 
tuberculosis H37Rv. ethyl 4- [3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl]-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5 carboxylate and ethyl 4-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-
4-yl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 63 were shown to be the most 
active compounds and found to be more potent than isoniazid.
 [18] 
 
 
 
ANTI TUMOR ACTIVITY; 
Monastrol is the first Biginelli compound which has excellent anticancer activity, further a series 
of compounds for their ability to inhibit Eg5 activity has been investigated using two in vitro 
steady-state ATPase assays (basal and microtubule-stimulated) as well as a cell-based assay. 
[18] 
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ANTI HIV AGENTS: 
Batzelladine derivatives of DHPMs obtained from marine natural source have promising anti 
HIV activity. These low molecular weight derivatives inhibit the binding of HIVgp-120 to CD4 
cells. 
[18]
 
 
ANTI EPILEPTICS: 
Phenobarbital is well known drug for epilepsy. Biginelli compounds have similar structural 
framework and have shown promising anti-epilepsy activity. 
[18]
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AIM AND OBJECTIVE OF THE STUDY 
 
With the ongoing progress in protein crystallography and NMR, structure-based drug design is 
gaining increasing importance in the search for new drugs. Modeling starts from the 3D structure 
of a target protein in order to construct molecules which are complementary to a binding site, in 
their geometry as well as in the pattern of their physicochemical properties around the molecules 
The present study relates to the synthesis of various derivatives and subsequent screening for 
their anti-tubercular activity. Due to several toxic effects of isoniazid, attempts were made to 
eliminate the toxicophore and substituting with a group contributing to the anti-tubercular action. 
This work also aims the same motive and the compounds were synthesized according to the 
developed and valid synthetic route. 
 
DOCKING: 
Several chemical libraries containing various scaffolds will be sketched and docked against the 
3D structure of DprE1. The compounds for the synthesis will be chosen based on the high G-
Score and their feasibility in synthetic chemistry. 
 
SYNTHESIS: 
 
Based upon the Docking parameters, the following compounds will be synthesized 
 
A. Synthesis of 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one(MBS2) 
B.  Synthesis of 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one (MBS3) 
C. Synthesis of 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
(MBS 6): 
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CHARACTERIZATION: 
The above compounds will be characterized by using Infrared Spectroscopy, Nuclear Magnetic 
Spectroscopy and Mass spectroscopy. 
 
BIOLOGICAL EVALUATION: 
The synthesized compounds will be screened for their anti-tubercular activity by various 
in-vitro methods. 
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REVIEW OF LITERATURE 
The purpose of a literature review is to: 
 
 Establish a theoretical framework for a topic / subject area 
 Define key terms, definitions and terminology 
 Identify studies, models, case studies etc supporting a topic 
 Define / establish an area of study. 
The review on following works provided basic information about the target enzyme, 
DprE1 and its function 
Maria Loreto Incandela.,et al,(2013) reported that DprE1, a new taxonomic marker in 
mycobacteria
.[19] 
Sarah M. Batt, et al., (2012) Structural basis of inhibition of Mycobacterium tuberculosis DprE1 
by benzothiazinone inhibitors.
[14] 
The following works throws a light upon the various genomic aspects of 
M.tuberculosis and also various targets intended for drug action 
 
Donald R Ronning., et, al., (2013) Targeting the mycobacterial envelope for tuberculosis drug 
development
[20] 
Véronique Dartois., et, al.,(2012) reviewed the  Role of Transport Mechanisms in 
Mycobacterium tuberculosis Drug Resistance and Tolerance
[21] 
Sarala Menon, et al, (2012), studied the Drug resistance profiles of Mycobacterium tuberculosis 
isolates to first line anti-tuberculous drugs
.[22]  
P.Mudassar., et al.,(2011) Had a Brief review on Multi Drug resistant Mycobacterium 
tuberculosis
.[23] 
Christian Lienhardt., et al.,(2010)  Had a review on New drugs and new regimens for the 
treatment of tuberculosis: review of the drug development pipeline and implications for national 
programmes
.[24] 
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Sarah L. Kinnings., et al,(2010), reviewed  the Mycobacterium tuberculosis Drugome and Its 
Polypharmacological Implications.
[25]
 
The review on following works provided ideas for synthesis of the desired chemical 
entities 
 
Yaghoub Sarrafi., et al., (2013), Mesoporous SBA-15 nanoparticles: An efficient and eco-
friendly Catalyst for onepot synthesis of 3, 4-dihydropyrimidin-2(1H)-ones under solvent-free 
conditions. 
[26] 
 
Shrivastav Pranav S., et al.,(2013)Application of La(III)-, Pr(III)-, Nd(III)- AND Sm(III)-
polychelates as catalyst for biginelli reactions. 
[27] 
 
Manjusha V. Yadav., et al.,(2013), Microwave assisted Biginelli’s synthesis of 3,4-
dihydropyrimidin-2(1H)-ones using 1, 3, 5-triazine-2, 4, 6-triyltrisulfamic acid as heterogeneous 
and recyclable catalyst
[28] 
 
IBRAHIM A. I. ALI., et al., (2013) synthesized, One-pot Synthesis of 3,4-dihydropyrimidin-2-
(1H)-one / thiones, bearing Sugar Side Chain Using Samarium Chloride as a Catalyst. 
[29] 
 
Rajendra P. Pawar., et al., (2013), an efficient synthesis of 4-aryl-substituted 3,4-
dihydropyrimidin-2(1h)-ones using nanocomposite ferrite catalyst. 
[30]
 
 
 Boudjemaa Boumoud., et al., (2013) synthesized a One-Step Multicomponent Synthesis of2-
Oxo-Quinolin-3-yl-Dihydropyri-midinoneand 2-oxo-1,2-Dihydroquinolin-3-yl- 
tetrahydroquinazolinedioneDerivatives. 
[31] 
 
K.Padmaja., et al., (2013) reviewed biological activities of dihydro pyrimidinones / thiones. 
[32] 
 
Jagir S. Sandhu., et al.,(2012), had review on Past, present and future of the Biginelli reaction: a 
critical perspective. 
[18]
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Srinivasa Rao Jetti., et al., (2012),synthesized a Carbon-Based Solid Acid as an Efficient and 
Reusable Catalyst for the Synthesis of 4,6-Diarylpyrimidin-2(1H)-ones under solvent-free 
conditions.  
[33]
 
 
 
M. Jalali., et al,(2012) studied and reported Antimicrobial evaluation of some novel derivatives 
of 3,4- dihydropyrimidine-2(1H)-one.
[34]
 
Ridha BEN SALEM.,et al.,(2012) synthesized some 3,4-dihydropyrimidinones catalyzed by 
ammonium chloride or montmorillonite ksf without solvent under ultrasonic irradiation. 
[35] 
 
Mahesh P. Davadra., et al.,(2012) An efficient three component one-pot synthesis of some new 
tetrahydroindeno-[1,2-d]pyrimidinone and dihydro-1H-indeno[1,2-d]pyrimidine derivatives 
using Antimony (III) chloride as a catalyst and investigation of their antimicrobial activity. 
[36] 
 
Shivaji Pandit., et al.,(2009) synthesized some 5 unsubstituted -3,4-dihydropyridine- 
2-(1h)- ones using nbs as a catalyst under solvent free conditions.
 [37] 
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Majid M. Heravi., et al., (2008), Three-component one-pot synthesis of 4,6-diarylpyrimidin- 
2(1H)-ones under solvent-free conditions in the presence of sulfamic acid as a green and reusable 
catalyst.
 [38] 
 
D. Subhas Bose., et al.,(2005) Had a New protocol for Biginelli reaction-a practical synthesis of 
Monastrol. 
[39] 
 
Jung Yun Do., et al., (2008),  Synthesis of 3,4-Dihydropyrimidin-2(1H)-ones Using HClO4-
SiO2 as a Heterogeneous and Recyclable Catalyst. 
[40] 
 
 
M. P. Kaushik., et al.,(2007) Synthesized 4-Aryl Substituted 3,4-Dihydropyrimidinones Using 
Silica-chloride Under Solvent Free Conditions. 
[41]
 
K. VIJAY, S. GANAPATY., et al.,(2010), Synthesis, Characterization and Biological Evaluation 
of Some Dihydropyrimidinones 
[42]
 
 
S. Kakaei., et al.,(2010), Green procedure for synthesis of 3, 4 dihydropyrimidinones 
using 12-molybdophosphoric acid, as a catalyst and solvent free condition under microwave 
irradiation 
[43]
 
 
The following literatures were surveyed in-depth to provide supporting data for the 
drug design study. 
 
T.S. Chitre, et al., (2011), Design, Synthesis, Docking and Anti-mycobacterial activity of  some 
novel thiouracil derivatives as thymidine monophoshate kinase (TMPKmt) inhibitors.
[44]
 
 
Himaja.M., et al., (2011), Synthesis, Docking studies and Antioxidant activity of  Linear 
Tetrapeptide Fayv.
[45]
 
 
Deepak. D. Borkar., et al.(2012), Design and Synthesis of p-hydroxybenzohydrazide Derivatives 
for their Antimycobacterial Activity. 
[46]
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The review on following works revealed the basics of Alamar blue assay for 
evaluating the anti-mycobacterial action. 
 
David A. J. Moore., et al., (2008), Inter- and Intra-Assay Reproducibility of Microplate Alamar 
Blue Assay Results for Isoniazid, Rifampicin,Ethambutol, Streptomycin, Ciprofloxacin, and 
Capreomycin Drug Susceptibility Testing of Mycobacterium tuberculosis. 
[47] 
 
Todd P. Primm., et., al(2007), Recent Advances in Methodologies for the Discovery of 
Antimycobacterial Drugs.
[48]
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MATERIALS AND METHODS 
 
1. DOCKING: 
 
A. PROTEIN PREPARATION: 
A typical PDB file consists only of heavy metals, can contain waters, cofactors and metal ions 
and can be multimeric. The structure generally has no information on bond orders, topologies, or 
formal atomic charges. Terminal groups can also be misaligned, because the X-ray structure 
analysis cannot easily distinguish between O and NH2 ion. Ionization and tautomeric states are 
usually unassigned. GLIDE® calculations use an all atom force-field for accurate energy 
evaluation. Thus, GLIDE® requires bond orders and ionization states to be properly assigned 
and performs better when side chains are reoriented when necessary and steric clashes are 
relieved. 
[49,50]
 
 
The steps by which protein preparation was carried out: 
 The ligand/protein co crystallized structure, from PDB was imported into maestro. The 
preparation component of a protein preparation facility requires an identified ligand. 
 
 The protein-ligand complex was identified for its form as dimer or other multimer 
containing duplicate binding sites and duplicate chains that were redundant, redundant 
binding sites and the associated chains were removed by picking and deleting molecules 
or chains. 
 Located waters that need to be kept, and others were then deleted. The waters that bridge 
between the ligand and protein were sometime retained and all the other waters (except 
those coordinated to metals) were deleted. If waters are added then hydrogen would be 
automatically added and the orientations of water molecules were checked once again. 
 Adjust the protein, metal ions, and cofactors were adjusted. Problems in the PDB protein 
structure that need to be repaired are done. Covalent bonds from metal ions to the protein 
are changed to zero-order bonds, and the formal charges on the metal and the ligating 
groups are adjusted to appropriate values. 
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 A restrained minimization of the protein structure run reorients side chain hydroxyl 
groups and alleviates potential steric clashes. The minimization is restrained to the input 
protein coordinates by a user-selected RMSD tolerance. 
 The ligand bond orders and formal charges were adjusted.  
 
B. LIGAND PREPARATION: 
[49,51] 
Ligand preparation is designed to prepare high quality, 3D structures for large numbers of drug 
like molecules. The structures that are docked must have actual ligand structures and should 
meet the following conditions: 
 They must be three dimensional. 
 They must have realistic bond lengths and bond angles. 
 They must each consist of a single molecule that has no covalent bonds to the receptor, 
with no accompanying fragments, such as counter ions and solvent molecules. 
 They must have all their hydrogens. 
 They must have an appropriate protonation state for physiological pH values 
(around 7). 
The LigPrep process consists of a series of steps that perform conversions, apply corrections to 
the structures, eliminate unwanted structures, and optimize the structures. The simplest use of 
LigPrep produces a single low-energy 3D structure with correct chiralities for each successfully 
processed input structure. LigPrep can also produce a number of structures from each input 
structure with various ionization states, tautomers, stereochemistries, and ring conformations, 
and eliminate molecules using various criteria including molecular weight or specified numbers 
and types of functional groups present. 
 
C. RECEPTOR GRID GENERATION: 
[49,51] 
The shape and properties of the receptor are represented on a grid by several different sets of 
fields that provide progressively more accurate scoring of the ligand poses. For receptors that 
adopt more than one conformation on binding, grids must be prepared for each conformation to 
ensure that possible actives are not missed. The receptor grid defines the receptor structure by 
excluding any co-crystallized ligand that might be present, determine the position and the size of 
the active site as it will be represented by receptor grids, set up glide constraints, and set up 
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flexible hydroxyl groups. Receptor grid generation requires a prepared structure: an all-atom 
structure with appropriate bond orders and formal charges. 
 
D. LIGAND DOCKING: 
Glide ligand docking jobs require a set of previously calculated receptor grids and one or more 
ligand structures. The ligand structures must satisfy the conditions listed above. Information on 
setting up grid generation jobs is given under. Preparation of the ligands before docking is 
strongly recommended. LigPrep or macro Model can be used to prepare ligands. If a correct 
Lewis structure cannot be generated for a ligand, it is skipped by the docking job. 
 
E. DOCKING AND SCORING FUNCTION: 
[49,50]
 
The ligands were docked with the active site using the ‘Extra precision’ Glide algorithm. Glide 
uses a hierarchical series of filters to search for possible locations of the ligand in the active-site 
region of the receptor. Final scoring of docked ligand is carried out on the energy-minimized 
poses Glide Score scoring function. Glide Score is based on ChemScore, but includes a 
stericclash term and adds buried polar terms devised by Schrödinger to penalize electrostatic 
mismatches. 
GScore = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB + Site Where, 
vdW: - Van der Waal energy; Coul: - Coulomb energy; Lipo: - Lipophilic contact term; HBond: 
- Hydrogen-bonding term; Metal: - Metal-binding term; BuryP: - Penalty for buried polar 
groups; RotB: - Penalty for freezing rotatable bonds; Site: - Polar interactions at the active site; 
and the coefficients of vdW and Coul are: - a = 0.065, b = 0.1 
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 DOCKING OF dprE1: 
Crystal structure of (PDB code-4FDO) was used for the study. The 3D structurewas downloaded 
from the Protein Data Bank (PDB) and loaded to the Maestro®Workbench. The hydrogen atoms 
were added to the proteins and further minimization was performed using protein preparation 
wizard. Structure based docking studies were carried out using GLIDE® on dprE1inhibitors and 
generated best docking poses. During the docking, GLIDE® initially performs a complete 
systematic search of the conformation, orientation, and position of a compound in the defined 
binding site and eliminates unwanted poses using scoring and energy optimization. The best 
poses were selected based on the scoring functions and quality of pose orientation within the 
active site amino acids. The docking scores were examined and the compounds showing high 
docking score were chosen for synthesis. 
 
INTERACTIONS 
The following are the pictographic representation of the docked compounds (MBS2,MBS3, 
MBS6) with dprE1 respectively 
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                                             MBS2 Docked with dprE1 
 
 
Ligand interaction diagram of MBS2 
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                                             MBS3 docked with dprE1 
 
 
Ligand Interaction diagram of MBS3 
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MBS6 docked with dprE1 
 
Ligand Interaction Diagram of MBS6 
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2. SYNTHETIC METHDOLOGY 
 
Synthesis of 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-
2(1H)-one(MBS2) 
A mixture containing 1mmol of 4-Acetyl pyridine, 1 mmol of 4 hydroxy benzaldehyde, urea 1.5 
mmol and benzytriethylammonium chloride 10 mol% was refluxed for 2hrs, completion of the 
reaction was confirmed by TLC, then the reaction mixture was poured onto crushed ice and 
stirred for 5-10min. The solid separated was filtered under suction, washed with ice-cold water, 
and then recrystallized from hot ethanol.  
N
CH3
O
HO
OH
NH2
NH2
O
N
NH
N
H
O
OH
+ +
BTEAC
Reflux 1 - 2 hrs
 
 
Synthesis of 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-
one (MBS3) 
 
A mixture containing 1mmol of 4-Acetyl pyridine, 1 mmol of 4 chloro benzaldehyde, urea 1.5 
mmol and benzytriethylammonium chloride 10 mol% was refluxed for 2hrs, completion of the 
reaction was confirmed by TLC, then the reaction mixture was poured onto crushed ice and 
stirred for 5-10min. The solid separated was filtered under suction, washed with ice-cold water, 
and then recrystallized from hot ethanol. 
                                                                                       Materials and Methods 
 
Department of Pharmaceutical Chemistry Page 40 
 
N
CH3
O
HO
Cl
NH2
NH2
O
N
NH
N
H
O
Cl
+ +
BTEAC
Reflux 1 - 2 hrs
 
 
 
Synthesis of 4-(4-dimethylamino)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-
2(1H)-one (MBS6) 
A mixture containing 1mmol of 4-Acetyl pyridine, 1 mmol of dimethyl aminobenzaldehyde, urea 
1.5 mmol and benzytriethylammonium chloride 10 mol% was refluxed for 2hrs, completion of 
the reaction was confirmed by TLC, then the reaction mixture was poured onto crushed ice and 
stirred for 5-10min. The solid separated was filtered under suction, washed with ice-cold water, 
and then recrystallized from hot ethanol.  
N
CH3
O
HO
N
CH3 CH3
NH2
NH2
O
N
NH
N
H
O
N
CH3CH3
+ +
BTEAC
Reflux 1 - 2 hrs
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JUSTIFICATION OF PURITY 
 
A. THIN LAYER CHROMATOGRAPHY: 
 
Precoated aluminium TLC plates were used. Solutions of the reactants and products 
were prepared by dissolving them in methanol. 
Stationary Phase : Precoated Silica Gel Plates 
Mobile Phase : Chloroform : Ethanol (3:7) 
Visualization : Iodine Vapors and UV chamber 
A single spot not corresponding to the parent compound was noticed and hence the 
purity of the synthesized compounds was justified. 
 
B. MELTING POINT: 
The melting points of synthesized compounds were determined by open tube 
capillary method with an aid of a melting point apparatus. The melting points were 
sharp and were presented uncorrected. 
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CHARACTERISATION STUDIES 
 
 
A. INFRA RED (IR) SPECTROSCOPY: 
The recrystallised compounds were subjected to IR spectral analysis for functional 
group identification using KBr pellet method. Infra Red Spectra was recorded using 
ABB (MB 3000) spectrophotometer. 
 
B. NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY: 
1H NMR spectra was recorded on Bruker Advance III 500MHz NMR spectrometer. 
Samples were prepared by dissolving a minute quantity of pure compounds in 
DMSO. Chemical shifts were reported in parts per million (ppm) 
 
C. MASS SPECTROSCOPY: 
Mass Spectra was recorded on Shimadzu HPLC-MS using Electron Spray Ionization 
Technique and was quantified using Lab Solutions Software 7.0, Samples were 
prepared by dissolving a minute quantity of pure compounds in methanol. The 
fragmentation patterns were reported in m/z values. 
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 3.  REACTANT PROFILE 
 
A. 4-Acetyl Pyridine 
 
 
 
 
 
Molecular Formula:                                                C7H7NO 
Formula Weight:                                                     121.14 
Boiling Point:                                                          212
o
C 
Description:                                                             Light yellow liquid  
 
B. Urea 
NH2
NH2
O
 
 
 
Molecular Formula                                                       CH4N2O 
Molecular Weight                          60.06 
Description White solid 
Melting point  133-135 
o
C 
 
 
 
N
CH3
O
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C. 4 Hydroxy benzaldehyde 
 
 
 
 
Molecular Formula                                                                   C7H6O2 
Molecular Weight                                                                     121.12 
Description                                                                           Light yellow to light brown 
Boiling point                                                                             191 
o
C 
 
D. P Chloro benzaldehyde 
H O
Cl
 
 
Molecular Formula                                                                   C7H5 ClO 
Molecular Weight                                                                     140.57 
Description                                                                           White crystalline solid 
Melting point                                                                              46 
o
C 
 
H O
OH
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E. Dimethylamino Benzaldehyde 
 
 
 
 
Molecular Formula                                                                   C9H11NO  
Molecular Weight                                                                     149.19 
Description                                                                           White crystalline powder  
Melting point                                                                             72-75 
o
C  
 
F: Benzyltriethylammonium chloride 
 
 
Molecular Formula                                                                   C13H22ClN 
Molecular Weight                                                                     227.77 
Description                                                                           white to light yellow crystal powder 
Melting point                                                                             239 
o
C  
 
 
 
 
H O
N
CH3CH3
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4. TOXICITY RISK ASSESSMENT 
All the data set molecules were subjected to the toxicity risk assessment by using Osiris program, 
which is available online. The OSIRIS property Explorer shown in this page is an integral part of 
Actelion's in house substance registration system. It allows drawing chemical structures and also 
calculates various drug relevant properties whenever a structure is valid. Prediction results are 
color coded in which the red colour shows high risks with undesired effects like mutagenicity or 
a poor intestinal absorption and green colour indicates drug-conform behavior. 
Molecular property prediction includes 
 Toxicity risk assessment 
 clogP predicition 
 Solubility prediction 
 Molecular weight 
 Drug likeness prediction 
 Drug likeness score 
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Toxicity assessment for  4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-
one(MBS2) 
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Toxicity Assessment for 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-
one (MBS3) 
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Toxicity Assessment for Synthesis of 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-
dihydropyrimidin-2(1H)-one (MBS 6): 
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MICROBIOLOGICAL ASSAY 
Microbial assays or microbiological assays is a type of bioassay and are designed to analyse the 
compounds or substances which have effect on micro-organisms. 
 
Microbiological assay is defined as the determination or estimation of concentration or potency 
of an antibiotic by means of measuring and comparing the area of zone of inhibition or turbidity 
produced by test substance with that of standard over a suitable microbe under standard 
conditions. 
 
So as definition says the hypothesis is that when an antibiotic is administered, there is inhibition 
in the growth of microbe as indicated by decrease in area of zone of microbial colony on 
nutrition media or decrease in turbidity due to decrease in microbial concentration. 
 
TYPES OF MICROBIOLOGICAL ASSAY: 
REDOX BASED  METHODS: 
Microplate Alamar blue assay.  
Resazurin Microtiter Assay, REMA, or Microdilution Resazurin Assay, MRA.  
Tetrazolium Dyes, Tetrazolium Microplate Assay, TEMA. 
 
REPORTER GENE-BASED METHODS:  
Green Fluorescent Protein Microplate Assay, GFPMA;  
Luciferase Assays;  
Beta-Galactosidase Assays. 
 
OTHER METHODS:  
BACTEC 460 TB;  
Nitrate Reductase Assay, NRA; 
Disk Diffusion; Visual Microbroth, or Broth Microdilution;  
Malachite Green;  
STC Agar; Flow Cytometry. 
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MICROPLATE ALAMAR BLUE ASSAY: 
 
MABA is clearly the standard in the field for HTS of compounds against mycobacteria, and is 
the most widely cited. The primary reference for the method is Collins and Franzblau in 1997. In 
that study, MABA was effective with MTB H37Rv, H37Ra and M. avium strain ATCC 25291, a 
relatively virulent isolate. MABA is reliable with clinical isolates of MTB and MAC. MABA has 
also been applied to M. kansasii and M. malmoense, as well as M. leprae. In addition to 
screening and sensitivity applications, MABA has also been used in patient treatment follow-up. 
MABA can operate in simple colorimetric mode with visual reading (blue to pink change 
indicates viability, with the MIC recorded as the lowest compound concentration in wells which 
remain blue). Newly synthesized product was assayed in vitro for anti tubercular activity. 
 
Evaluation of the products for their in vitro antitubercular activity against Mycobacterium 
Tuberculosis H37Rv using MicroplateAlamar Blue Assay (MABA) biological test was done. 
This methodology is nontoxic, uses a thermally-stable reagent and shows good correlation with 
proportional and BACTEC radiometric methods. 
[48, 52] 
 
Anti-TB activity using Alamar Blue Dye 
 The anti mycobacterial activity of compounds were assessed against M. tuberculosis using 
microplate Alamar Blue assay (MABA). 
1. This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method. 
2. Briefly, 200µl of sterile deionzed  water was added to all outer perimeter wells of sterile 
96 wells plate to minimized evaporation of medium in the test wells during incubation. 
3. The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial dilution of 
compounds were made directly on plate. 
4. The final drug concentrations tested were 100 to 0.2 µg/ml. 
5. Plates were covered and sealed with parafilm and incubated at 37ºC for five days. 
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6. After this time, 25µl of freshly prepared 1:1 mixture of Almar Blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs.  
7. A blue color in the well was interpreted as no bacterial growth, and pink color was scored 
as growth.  
8. The MIC was defined as lowest drug concentration which prevented the color change 
from blue to pink. 
[52,53] 
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PRODUCT PROFILE: 
4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one(MBS2) 
  
PHYSICO- CHEMICAL PROPERTIES: 
Description:     Brick Red colour solid 
Solubility:    Soluble in Ethanol, Methanol. 
Molecular Formula:   C15H13N3O2 
Formula Weight :  267.28262 
Composition:                               C(67.40%) H(4.90%) N(15.72%) O(11.97%) 
Molar Refractivity:   73.73 ± 0.3 cm
3 
Molar Volume:     206.3 ± 3.0 cm
3 
Parachor:    562.5 ± 6.0 cm
3 
Index of Refraction:   1.633 ± 0.02 
Surface Tension:   55.2 ± 3.0 dyne/cm 
Density:    1.295 ± 0.06 g/cm
3 
Polarizability:      29.23 ± 0.5 10
-24
cm
3 
Monoisotopic Mass:    267.100777 Da 
Nominal Mass:    267 Da 
Average Mass:    267.2826 Da 
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 Synthesis of 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one (MBS3) 
 
  
PHYSICO-CHEMICAL PROPERTIES: 
Description:    Pale Brown colour solid 
Solubility:    Soluble in Ethanol, Methanol, DMSO. 
Molecular Formula:  C15H12ClN3O 
Formula Weight:  285.72828 
Composition:   C(63.05%) H(4.23%) Cl(12.41%) N(14.71%) O(5.60%) 
Molar Refractivity:                       76.74 ± 0.3 cm
3 
Molar Volume:                             219.8 ± 3.0 cm
3 
Parachor:                                    584.4 ± 6.0 cm
3 
Index of Refraction:               1.615 ± 0.02 
Surface Tension:   49.9 ± 3.0 dyne/cm 
Density:                1.299 ± 0.06 g/cm
3 
Polarizability:                            30.42 ± 0.5 10
-24
cm
3 
Monoisotopic Mass:   285.06689 Da 
Nominal Mass:   285 Da 
Average Mass:    285.7283 Da 
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Synthesis of 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
(MBS 6): 
 
PHYSICO- CHEMICAL PROPERTIES: 
Description:                   Orange color Solid. 
Solubility:                     Soluble in Ethanol, Methanol. 
Molecular Formula      C17H18N4O 
Formula Weight      294.35102 
Composition                  C(69.37%) H(6.16%) N(19.03%) O(5.44%) 
Molar Refractivity      86.16 ± 0.3 cm
3
 
Molar Volume     245.8 ± 3.0 cm
3
 
Parachor                        651.9 ± 6.0 cm
3
 
Index of Refraction    1.618 ± 0.02 
Surface Tension    49.4 ± 3.0 dyne/cm 
Density                1.197 ± 0.06 g/cm
3
 
Polarizability                34.15 ± 0.5 10
-24
cm
3
 
Monoisotopic Mass    294.148061 Da 
Nominal Mass    294 Da 
Average Mass              294.351 Da 
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RESULTS AND DISCUSSION 
 
 
 
DOCKING STUDIES: 
 
To predict the possible binding modes and enzyme inhibition mechanism, compounds were 
docked onto the active sites of  dprE1using GLIDE, the grid-based ligand docking with 
energetics software from Schrödinger. The best pose was selected based on Glide score and the 
favorable interactions formed between the compound and amino acid residues of the dprE1 
active site. All the ligands in the complex structures showed the hydrogen bond interactions with 
ARG 58, ARG 58, LYS 418. This clearly indicates that these hydrogen bonded amino acids play 
a crucial role in inhibition activity. The docking scores for these compounds are reported on the 
table. 
 
Rewards: 
 
 
 
 
 
 
Penalities: 
 
 
 
Ligand 
G 
Score 
Dock 
Score 
Lipophilic 
EvdW 
Phob 
En 
Phob 
EnHB 
Phob 
EnPairHB HBond Electro 
Site 
map PiCat ClBr 
Low 
MW 
MBS2 -7.38 - -4.17 0 -1.5 0 -1.01 -0.25 -0.17 0 0 -0.5 
MBS3 -6.27 - -3.29 -0.26 -1.5 0 -0.67 0.08 -0.37 0 0 -0.5 
MBS6 -6.97 - -4.41 -0.3 -1.5 0 -0.22 0.15 -0.38 0 0 -0.5 
Ligand Penalties 
HB 
Penal 
Expos 
Penal 
Rot 
Penal 
EpikState 
Penalty Similarity Activity 
MBS2 0.01 0 0 0.21 -- - -7.38 
MBS3 0.05 0 0 0.19 -- 1 -6.27 
MBS6 0.02 0 0 0.18 -- 1 -6.97 
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Comparison of Glide score of compounds with Standard Drugs: 
Docking score of the 3 compounds were compared with that of standard drugs, that is Pyrazinamide, 
Ciprofloxacin and Streptomycin, and the results were shown below. 
 
COMPOUNDS DOCKING SCORE(Glide)kcal/mol 
Pyrazinamide -5.8 
Ciprofloxacin -3.8 
Streptomycin -5.7 
INH -5.0 
MBS 2 -7.8 
MBS 3 -6.2 
MBS 6 -6.7 
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SYNTHESIS AND CHARACTERIZATION 
 
 
The 1H-NMR spectra were recorded on Bruker AC Spectrometer using DMSO as Solvent. The 
data are given in parts per million(ppm) and are referenced to an  internal standard of 
tetramethylsilane (TMS,δ 0.00 ppm). Peak Multiplicity is reported as s (singlet), d (doublet), dd 
(double doublet), t (triplet), and m(multiplet). Melting points were measured on SH apparatus. 
 
Physical Properties of Synthesized compound: 
 
S.No Compound 
ID 
Structure Mass Solubility Appearance 
1. MBS-2 
N
NH
N
H
O
OH
 
266.0 Ethanol, 
Methanol, 
DMSO. 
Pale Orange 
solid 
2. MBS-3 
N
NH
N
H
O
Cl
 
284.01 Ethanol, 
Methanol, 
DMSO. 
Pale Brown 
solid 
3. MBS-6 
N
NH
N
H
O
N
CH3CH3
 
293 Ethanol, 
Methanol, 
DMSO. 
Orange solid 
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CHARACTERIZATION STUDIES: 
 
Compound 1: MBS 2 
 
Analytical data of 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
 
 
N
NH
N
H
O
OH
 
 
Molecular Formula:          C15 H13 N3 O2 
 
Melting Point:                   105-110
o
c 
 
Yield:                                   85% 
 
IR V 
cm-1
 (KBr):    3379 cm
-1
 (OH str) 
 
 3217 cm
-1
(N-H str) 
                               
                                 3062 cm
-1
(C-H str) 
 
                                 1596 cm
-1
 (C=O str) 
 
                                 1450 cm
-1
(C=C str) 
 
                                 1242 cm
-1
(C-N str) 
 
MASS (m/z):              266(M+ peak) 
 
NMR:           δ 1.20 – 1.40 [m, 1H,Aliphatic CH] 
         δ 2.4 – 2.5 [s, 1H,Aliphatic CH] 
      δ 6.90 – 6.97 [m, 2H,Ar - CH] 
      δ 7.50 – 7.51[s,1H,Ar-H] 
      δ 7.98 – 8.78 [m, 5H, Ar – H] 
      δ 9.0 – 9.4 [1H,OH] 
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IR SPECTRA OF 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
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MASS SPECTRA OF 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
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NMR SPECTRUM OF 4-(4-hydroxyphenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
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Compound 2: MBS  3 
 
Analytical data of 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
 
 
N
NH
N
H
O
Cl
 
Molecular Formula:          C15 H12 N3 O Cl 
 
Melting Point:                   95-97
o
c 
 
Yield:                                 90% 
 
IR V 
cm-1
 (KBr) :     3209 cm-1(N-H str) 
                               
                                   3031 cm
-1 
(C-H str) 
 
                                   1596 cm
-1
 (C=O str) 
 
                                   1450 cm
-1
(C=C str) 
 
                                   1242 cm
-1
(C-N str) 
                                      
 817 cm
-1
(C-Cl str) 
 
 
Mass (m/z):           284 (m+ peak) 
 
NMR:                    δ 1.1 – 2.5 [d,2H,Aliphatic CH] 
                      δ 3.4 – 3.5 [s, 2H,NH] 
                    δ 7.2 – 8.7 [m, 8H,Aromatic] 
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IR SPECTRUM OF  4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
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MASS SPECTRUM OF 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                       Results and Discussion 
 
Department of Pharmaceutical Chemistry Page 66 
 
 
 
 
NMR SPECTRUM OF 4-(4-chlorophenyl)-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one 
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Compound 3: MBS 6 
 
Analytical data of 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-one. 
 
 
 
N
NH
N
H
O
N
CH3CH3
 
 
 
Molecular Formula:          C17 H18 N4 O 
 
Melting Point:                   102 
o
c 
 
Yield:                                   75% 
 
 
IR V 
cm-1
 (KBr) :   3379 cm-1(N-H str) 
                               
                                  3031 cm
-1
(C-H str) 
 
                                  2923 cm-1(methylene CH Str) 
 
                                   1596 cm
-1
 (C=O str) 
 
                                   1442 cm
-1
(C=C str) 
 
                                   1357 cm
-1
(C-N str) 
                                      
Mass (m/z):           294 (m+ peak) 
 
NMR:                   δ 2.3 – 2.5 [s,1H,Aliphatic CH] 
                                δ 2.8  - 3.0 [s,6H, N(CH3)2] 
                     δ 3.1 – 3.7 [s, 1H,CH] 
                   δ 6.9 – 8.7 [M, 8H,Ar-CH]
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IR SPECTRUM OF 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-2(1H)-
one. 
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MASS SPECTRUM OF 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-
2(1H)-one. 
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NMR SPECTRUM OF 4-[4-(dimethylamino)phenyl]-6-(pyridin-4-yl)-3,4-dihydropyrimidin-
2(1H)-one. 
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BIOLOGICAL SCREENING 
 
The synthesized compounds were screened for their in-vitro anti mycobacterial activity 
by means of alamar blue assay. The compounds were tested in the concentration range 
of 100 to 0.8 μg/ml against M.tuberculosis H37Rv strain grown in Middlebrook 7H9 broth 
in 96 well titre plate. Pyrazinamide- 3.125μg/ml and Streptomycin- 6.25μg/ml were 
used as standards for comparison.  
A blue color in the well was interpreted as no bacterial growth so it is termed as  sensitive, and 
pink color was scored as growth and is referred as resistant. The MIC was defined as lowest drug 
concentration which prevented the color change from blue to pink. 
 
STANDARD DRUG PHOTOGRAPH 
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MABA REPORT OF THE SYNTHESIZED COMPOUNDS 
Samples 100µg/ml 50µg/ml 25µg/ml 12.5µg/ml 6.25µg/ml 3.12µg/ml 1.6µg/ml 0.8µg/ml 
MBS2 S S R R R R R R 
MBS3 S S R R R R R R 
MBS6 S S R R R R R R 
 
 
 
 
 
                           Anti Mycobacterial Activity of the Synthesized Compounds 
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TOXICITY RISK ASSESSMENT: 
The compounds were predicted to have low toxicity risks as per the OSIRIS Property Predictor 
Software. Prediction results are color coded and it indicates that all the three compounds has 
drug-conform behavior. 
MOLINSPIRATION: 
Molinspiration, a web based software was used to obtain parameter such as MiLogP, TPSA, drug 
likeness. MiLogP, is calculated by the methodology developed by Molinspiration as a sum of 
fragment based assistance and correction factors. MiLog P parameter is used to check good 
permeability across the cell membrane. TPSA is related to hydrogen bonding potential of 
compound. Number of rotatable bonds measures molecular flexibility.  Molinspiration helps to 
conform about the Lipinski’s rule of Five.  It helps to know about that Drug likeness of compound, 
and also helps to know about the Pharmacokinetics profile of the drug entity, that includes 
absorption, distribution, metabolism and excretion (“ADME”). 
Molinspiration results of compound MBS 2, MBS 3 and MBS 6 are shown below. 
 
 
                                                      Molinspiration result of MBS 2 
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Molinspiration result of MBS 3 
 
 
 
 
Molinspiration result of MBS 6 
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SUMMARY AND CONCLUSION 
 
 Decaprenylphosphoryl-b-d-ribose 2’-Epimerase 1(DprE1) a enzyme of Oxido Reductase 
family is a critical enzyme for the growth of Mycobacterium tuberculosis H37Rv. 
 From the review of literature DprE1 was chosen for our study for drug design. 
 A database of 100 molecules with high potential of inhibiting the target possessing PDB 
ID of 4FDO were carefully chosen by making changes into the lead molecule 3,4-
Dihydro pyrimidinones. 
 The 3D structure of hopeful molecules were docked against the 3D structure of 4FDO 
using the docking platform Glide
®  
(Grid Based Ligand Docking with Energetics). 
 Three compounds with good Glide score( lower Binding energy) were selected for 
laboratory synthesis. Reaction conditions were optimized. 
 The Compounds were labeled as MBS 2, MBS3, MBS6 were synthesized with 
satisfactory yield by Biginelli reaction. 
 The purity of the synthesized compounds were evaluated by melting point and TLC. 
Recrystallization was done. 
 The characterization of the synthesized compounds were done by Infrared, Nuclear 
magnetic resonance and Mass spectroscopic methods. 
 The synthesized compounds were subjected to computer aided drug design (CADD) 
tool,for toxicity risk assessment by OSIRIS property calculator. The results are color 
coded as green color which confirms the drug likeness. 
 The final pure compounds were screened for Antimycobacterial activity by in vitro 
method called Microplate Alamar Blue Assay(MABA). 
 The Minimum Inhibitory Concentration (MIC) of the synthesized compounds were at 
50mcg/ml against the MIC of known TB drugs Pyrazinamide: 3.125mcg/ml, 
Ciprofloxacin:  3.125mcg/ml and Streptomycin 6.25mcg/ml. 
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CONCLUSION 
 
Our work concludes that our synthesized molecules are effective in inhibiting 
Decaprenylphosphoryl-b-d-ribose 2’-Epimerase 1(DprE1) which is important for the growth of 
Mycobacterium tuberculosis.  
Further structural improvement in the structure of the synthesized compounds will give new 
outlook to the development of  promising molecules against the pathogen Mycobacterium 
tuberculosis.  
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